Baxter International Inc. (NYSE:BAX) Healthcare Business Recap

Industry Analysis

Baxter International Inc. (NYSE:BAX) is ranked 2^nd among 157 Medical Instruments and Supplier companies by market capitalization which stands at $30.35 billion. The company maintains the long term growth rate of 7.98 percent among its competitors. BAX is ranked 5^th in terms of revenue growth annually.

1^st Quarter 2012 Results:

Baxter International Inc. (NYSE:BAX) reported its total revenue to $3.38 billion for the quarter ended March 31^st, 2012 as compared to revenue of $3.28 billion for the same period prior year. Despite increase in its revenue the company ended in net profit of $588 million or profit of $1.04 per share as compared to net profit of $570 million or profit of $0.98 per share last year.

The company’s total assets accumulate up to $2.82 billion out of which current assets have the highest proportion standing at $19.07 billion. The company maintains strong short term liquidity position which is evident from its current ratio of 1.78 times.

Baxter International Inc.’s Competitors:

Covidien plc (NYSE:COV), C.R. Bard, Inc. (NYSE:BCR), ICU Medical, Incorporated (NASDAQ:ICUI), Teleflex Incorporated (NYSE:TFX), Hospira, Inc. (NYSE:HSP), CryoLife, Inc. (NYSE:CRY), Becton, Dickinson and Co. (NYSE:BDX), CareFusion Corporation (NYSE:CFN), Haemonetics Corporation (NYSE:HAE), and NxStage Medical, Inc. (NASDAQ:NXTM).